Literature DB >> 26492824

Potent and Selective Inhibitors of Trypanosoma cruzi Triosephosphate Isomerase with Concomitant Inhibition of Cruzipain: Inhibition of Parasite Growth through Multitarget Activity.

Elena Aguilera1, Javier Varela1, Estefanía Birriel1, Elva Serna2, Susana Torres2, Gloria Yaluff2, Ninfa Vera de Bilbao2, Beatriz Aguirre-López3, Nallely Cabrera3, Selma Díaz Mazariegos3, Marieta Tuena de Gómez-Puyou3, Armando Gómez-Puyou3, Ruy Pérez-Montfort3, Lucia Minini4, Alicia Merlino4, Hugo Cerecetto1,5, Mercedes González1, Guzmán Alvarez6,7.   

Abstract

Triosephosphate isomerase (TIM) is an essential Trypanosoma cruzi enzyme and one of the few validated drug targets for Chagas disease. The known inhibitors of this enzyme behave poorly or have low activity in the parasite. In this work, we used symmetrical diarylideneketones derived from structures with trypanosomicidal activity. We obtained an enzymatic inhibitor with an IC50 value of 86 nm without inhibition effects on the mammalian enzyme. These molecules also affected cruzipain, another essential proteolytic enzyme of the parasite. This dual activity is important to avoid resistance problems. The compounds were studied in vitro against the epimastigote form of the parasite, and nonspecific toxicity to mammalian cells was also evaluated. As a proof of concept, three of the best derivatives were also assayed in vivo. Some of these derivatives showed higher in vitro trypanosomicidal activity than the reference drugs and were effective in protecting infected mice. In addition, these molecules could be obtained by a simple and economic green synthetic route, which is an important feature in the research and development of future drugs for neglected diseases.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Chagas disease; Trypanosoma cruzi; cruzipain; enzyme inhibitors; multitarget drugs; triosephosphate isomerase

Mesh:

Substances:

Year:  2015        PMID: 26492824     DOI: 10.1002/cmdc.201500385

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  14 in total

1.  Development of a pharmacophore for cruzain using oxadiazoles as virtual molecular probes: quantitative structure-activity relationship studies.

Authors:  Anacleto S de Souza; Marcelo T de Oliveira; Adriano D Andricopulo
Journal:  J Comput Aided Mol Des       Date:  2017-08-09       Impact factor: 3.686

2.  Identification of 2-(4-N,N-Dimethylaminophenyl)-5-methyl-1-phenethyl-1H-benzimidazole targeting HIV-1 CA capsid protein and inhibiting HIV-1 replication in cellulo.

Authors:  Guzmán Alvarez; Lisa van Pul; Xavier Robert; Zoraima Artía; Ad C van Nuenen; Mathieu Long; Natalia Sierra; Williams Porcal; Neeltje A Kootstra; Christophe Guillon
Journal:  BMC Pharmacol Toxicol       Date:  2022-06-28       Impact factor: 2.605

3.  Optimization of a Bioluminescence Resonance Energy Transfer-Based Assay for Screening of Trypanosoma cruzi Protein/Protein Interaction Inhibitors.

Authors:  Jesica G Mild; Lucia R Fernandez; Odile Gayet; Juan Iovanna; Nelson Dusetti; Martin M Edreira
Journal:  Mol Biotechnol       Date:  2018-05       Impact factor: 2.695

Review 4.  Therapeutic targets for the treatment of microsporidiosis in humans.

Authors:  Bing Han; Louis M Weiss
Journal:  Expert Opin Ther Targets       Date:  2018-11-01       Impact factor: 6.902

5.  First characterization of a microsporidial triosephosphate isomerase and the biochemical mechanisms of its inactivation to propose a new druggable target.

Authors:  Itzhel García-Torres; Ignacio De la Mora-De la Mora; Gloria Hernández-Alcántara; Dora Molina-Ortiz; Silvia Caballero-Salazar; Alfonso Olivos-García; Gabriela Nava; Gabriel López-Velázquez; Sergio Enríquez-Flores
Journal:  Sci Rep       Date:  2018-06-05       Impact factor: 4.379

6.  Multi-Anti-Parasitic Activity of Arylidene Ketones and Thiazolidene Hydrazines against Trypanosoma cruzi and Leishmania spp.

Authors:  Guzmán Álvarez; Cintya Perdomo; Cathia Coronel; Elena Aguilera; Javier Varela; Gonzalo Aparicio; Flavio R Zolessi; Nallely Cabrera; Celeste Vega; Miriam Rolón; Antonieta Rojas de Arias; Ruy Pérez-Montfort; Hugo Cerecetto; Mercedes González
Journal:  Molecules       Date:  2017-05-07       Impact factor: 4.411

7.  Looking for combination of benznidazole and Trypanosoma cruzi-triosephosphate isomerase inhibitors for Chagas disease treatment.

Authors:  Elena Aguilera; Javier Varela; Elva Serna; Susana Torres; Gloria Yaluff; Ninfa Vera de Bilbao; Hugo Cerecetto; Guzmán Alvarez; Mercedes González
Journal:  Mem Inst Oswaldo Cruz       Date:  2018-03       Impact factor: 2.743

8.  Computational Drug Repositioning for Chagas Disease Using Protein-Ligand Interaction Profiling.

Authors:  Alfredo Juárez-Saldivar; Michael Schroeder; Sebastian Salentin; V Joachim Haupt; Emma Saavedra; Citlali Vázquez; Francisco Reyes-Espinosa; Verónica Herrera-Mayorga; Juan Carlos Villalobos-Rocha; Carlos A García-Pérez; Nuria E Campillo; Gildardo Rivera
Journal:  Int J Mol Sci       Date:  2020-06-16       Impact factor: 5.923

9.  Novel and Selective Rhipicephalus microplus Triosephosphate Isomerase Inhibitors with Acaricidal Activity.

Authors:  Luiz Saramago; Helga Gomes; Elena Aguilera; Hugo Cerecetto; Mercedes González; Mauricio Cabrera; Maria Fernanda Alzugaray; Itabajara da Silva Vaz Junior; Rodrigo Nunes da Fonseca; Beatriz Aguirre-López; Nallely Cabrera; Ruy Pérez-Montfort; Alicia Merlino; Jorge Moraes; Guzmán Álvarez
Journal:  Vet Sci       Date:  2018-08-23

10.  Looking for Novel Capsid Protein Multimerization Inhibitors of Feline Immunodeficiency Virus.

Authors:  Natalia Sierra; Christelle Folio; Xavier Robert; Mathieu Long; Christophe Guillon; Guzmán Álvarez
Journal:  Pharmaceuticals (Basel)       Date:  2018-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.